(VIANEWS) – The NASDAQ ended the session with ImmunoGen jumping 22.8% to $5.30 on Friday, after three successive sessions in a row of gains. NASDAQ jumped 0.69% to $12,226.58, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.
ImmunoGen’s last close was $4.32, 34.84% under its 52-week high of $6.63.
About ImmunoGen
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.61%.
More news about ImmunoGen (IMGN).
